Provided by Tiger Trade Technology Pte. Ltd.

Relmada Therapeutics, Inc.

5.90
-0.3550-5.68%
Volume:639.63K
Turnover:3.98M
Market Cap:618.33M
PE:-3.33
High:6.66
Open:6.50
Low:5.85
Close:6.25
52wk High:7.51
52wk Low:0.2430
Shares:104.89M
Float Shares:81.91M
Volume Ratio:0.54
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7693
EPS(LYR):-2.6515
ROE:-196.79%
ROA:-102.41%
PB:65.32
PE(LYR):-2.22

Loading ...

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for Ndv-01 in Non-Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Mar 09

Relmada Therapeutics Inc - Ndv-01 Demonstrates 76% 12-Month Complete Response Rate in High-Risk Nmibc

THOMSON REUTERS
·
Mar 09

Relmada Therapeutics Inc: Initial 3-Month Results From Phase 3 2L Bcg-Unresponsive Study Expected by Ye 2026

THOMSON REUTERS
·
Mar 09

Relmada Therapeutics Inc - Phase 3 Rescue Program Initiation for Ndv-01 Expected in Mid-2026

THOMSON REUTERS
·
Mar 09

Relmada Therapeutics Inc: Ndv-01 United States Ind Clearance Expected Mid-2026

THOMSON REUTERS
·
Mar 09

Relmada Therapeutics initiated with a Buy at Lucid Capital

TIPRANKS
·
Mar 02

Relmada Therapeutics Inc : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $8 From $1

THOMSON REUTERS
·
Jan 23

Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01

TIPRANKS
·
Jan 12

Relmada Therapeutics Inc - FDA Supports Randomized Trial for Ndv-01 in Intermediate-Risk Nmibc

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc - Receives FDA Feedback on Ndv-01 Studies

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc - FDA Supports Single-Arm Trial for Ndv-01 in High-Grade Nmibc

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc - to Start Registrational Trials in 1H 2026

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $9

THOMSON REUTERS
·
Dec 22, 2025

Relmada Therapeutics CFO Maged Shenouda Reports Acquisition of Common Shares

Reuters
·
Dec 16, 2025

Relmada Therapeutics Raises Executive Salaries in Amended Employment Agreements

Reuters
·
Dec 15, 2025

Mizuho Securities upgrades Relmada Therapeutics (RLMD) to a Buy

TIPRANKS
·
Nov 19, 2025

Relmada Therapeutics Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $10 From $1

THOMSON REUTERS
·
Nov 19, 2025

Relmada Therapeutics CAO and COO Chuck Ence Acquires Common Shares

Reuters
·
Nov 06, 2025

Relmada Therapeutics CFO Maged Shenouda Reports Acquisition of Common Shares

Reuters
·
Nov 06, 2025

Relmada Therapeutics announces FDA feedback on study paths for NDV-01

TIPRANKS
·
Nov 04, 2025